Medical inquiries

Connect with my medical science liaison

Chat live

Available Monday - Friday 9AM - 4:30PM ET

Call me now

Available Monday - Friday 9AM - 7:30PM ET

Email your inquiry

Call 1-800-526-7736

Available Monday - Friday 9AM - 8PM ET

Live video

Available Monday - Friday 9AM - 4:30PM ET

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

RYBREVANT® (amivantamab-vmjw)

Medical Information

+ Save link

Use of RYBREVANT in Combination with Immune Checkpoint Inhibitors

Last Updated: 04/30/2024

SUMMARY

RYBREVANT (amivantamab-vmjw) is a low fucose, fully-human immunoglobulin G1 (IgG1)-based bispecific antibody with immune cell-directing activity that targets epidermal growth factor receptor (EGFR) mutations and mesenchymal-epithelial transition (MET) mutations and amplifications in non-small cell lung cancer (NSCLC).¹
No prospective, randomized clinical studies were identified in the published literature that evaluated the use of RYBREVANT in combination with immune checkpoint inhibitors (programmed death-1 [PD-1], programmed death ligand-1 [PDL1], and cytotoxic Tlymphocyte-associated antigen-4 [CTLA-4] inhibitors) for the treatment of patients with NSCLC.
A preclinical study has evaluated the combinatorial activity of RYBREVANT and pembrolizumab in humanized head and neck squamous cell carcinoma (HNSCC) and lung squamous cell carcinoma (LUSC) mice models.²

Literature Search

A literature search of MEDLINE^®, Embase^®, BIOSIS Previews^®, and Derwent Drug File (and/or other resources, including internal/external databases) was conducted on 26 April 2024.

References

Show

1	Moores SL, Chiu ML, Bushey BS, et al. A novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor-resistant lung tumors. Cancer Res. 2016;76(13):3942-3953.
2	Kang S, Lim SM, Synn CB, et al. Combinatorial activity of amivantamab and pembrolizumab in head and neck squamous cell carcinoma and lung squamous cell carcinoma expressing wild-type EGFR and MET. Poster presented at: 2023 American Association for Cancer Research (AACR) Annual Meeting; April 14-19, 2023; Orlando, FL.